The Creating Hope Act, Section 908 of the FDA Safety and Innovation Act of 2012
This is a historic moment for the pediatric cancer and the pediatric rare disease community. On July 9, 2012, the President signed into law the FDA Safety and Innovation Act and with it, the first legislation to address the dire need for new drugs developed expressly for children with cancer and other life threatening diseases.
We want to thank Members of Congress and their staff whose vision and tireless advocacy ensured the passage of the Creating Hope Act.
We also want to thank the Food and Drug Administration for their leadership and commitment to find new ways to spur drug development for children with cancer and other life threatening diseases.
Finally, we want to thank the pediatric cancer community and the pediatric rare disease community whose mobilization behind the Creating Hope Act made it a reality.